Eterna Therapeutics and Factor Bioscience Announce New Data on Multi-Cell-Type Therapeutic Approach at American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting
Retrieved on:
Wednesday, May 17, 2023
Ionization, Spermine, Myelocyte, DNA, Gene, Macrophage, Gene editing, Cancer, Lipid, NK, Research, Cell, Los Angeles Convention Center, Element, Messenger, AAVS1, Acquisition, Patient, ERNA, Blood, Immune system, Entrepreneurship, LNP, Cytotoxicity, IPS, Safety, Society, ROR1, Vaccine, Antibiotics, Eterna
CAMBRIDGE, Mass., May 17, 2023 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna”), a life science company committed to realizing the potential of mRNA cell engineering to provide patients with transformational new medicines, and its discovery partner Factor Bioscience (“Factor”) today announced new data on an iPS cell-derived multi-cell-type therapeutic strategy for solid-tumor targeting, as well as advances in nucleic-acid delivery and targeted gene insertion, in eight poster presentations at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting, taking place May 16-20, 2023 at the Los Angeles Convention Center.
Key Points:
- “This approach has the potential to form the foundation of an entirely new class of cell therapies that could play an important role in treating cancer.
- In vitro studies with lymphoid and myeloid cells showed synergistic killing of SKOV3 ovarian tumor cells.
- This methodology has the potential to support the development of engineered cell therapies designed to express therapeutic proteins.
- The data presented show that the lipids identified may serve as components of next-generation, LNP-based mRNA and gene therapies.